Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
November 14, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has been named...
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
November 03, 2022 09:07 ET
|
Sana Biotechnology, Inc
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts...
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
November 02, 2022 16:05 ET
|
Sana Biotechnology, Inc
Expect to file IND this year for SC291 with potential clinical data in 2023 Followed by expected INDs for SG295 and SC276 in 2023 and SC451 in 2024 with potential clinical data in 2024 Q3 2022 cash...
Sana Biotechnology to Present at September 2022 Investor Conferences
September 09, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
August 04, 2022 16:05 ET
|
Sana Biotechnology, Inc
Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as...
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
June 17, 2022 09:00 ET
|
Sana Biotechnology, Inc
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune...
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
June 13, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will...
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory
June 01, 2022 16:05 ET
|
Sana Biotechnology, Inc
Replacement of Fremont, CA Facility Estimated to Save Over $100M in the Next Three Years Global Cell Therapy Manufacturing Expert Snehal Patel Appointed Head of Manufacturing Veteran Regulatory...
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
May 12, 2022 17:40 ET
|
Sana Biotechnology, Inc
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice...